Karyopharm Therapeutics (KPTI) Liabilities and Shareholders Equity (2012 - 2026)

Karyopharm Therapeutics (KPTI) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $108.4 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 34.06% year-over-year to $108.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $437.2 million (down 43.39% YoY) and the FY2025 annual result came in at $108.4 million, down 34.06% from the prior year.
• Liabilities and Shareholders Equity climbed to $108.4 million in Q4 2025, from $96.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $358.2 million in Q4 2022 to a low of $96.2 million in Q3 2025.
• A 5-year average of $230.2 million and a median of $247.3 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity advanced 17.32% — and 2025, when it tumbled 50.99%.
• Tracing KPTI's Liabilities and Shareholders Equity over 5 years: stood at $305.3 million in 2021, then grew by 17.32% to $358.2 million in 2022, then slumped by 32.87% to $240.4 million in 2023, then sank by 31.62% to $164.4 million in 2024, then plunged by 34.06% to $108.4 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $108.4 million (Q4 2025), $96.2 million (Q3 2025), and $104.9 million (Q2 2025), per Business Quant data.